FDA lifts Proellex clinical hold; NJ biotech stays strong through recession;

 @FierceBiotech: Covance plans 300 hires for Indiana campus. Report | Follow @FierceBiotech

 @JohnCFierce: Sharing data on failed Alzheimer's trials makes a lot of sense. It's also cool to see biopharma companies working together. | Follow @JohnCFierce

> FDA has lifted the full clinical hold on Repros Therapeutics' Proellex. Repros will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. Repros release

> BioNJ says the states biotech industry is still strong despite two years of economic challenges. The state now boasts 303 biopharma companies, up 28 percent from the 238 firmst in 2008. Report

> Only 38 percent of European biopharmaceutical companies feel that they have the ability to influence market access stakeholders, according to new research. Report

> A drug commonly used to treat gout may help patients with chronic kidney disease keep their condition in check and reduce the risk of heart problems, Spanish scientists said. Report

And Finally... Is manufacturing the 'stepchild' of pharma? Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.